• Company
• K-Bio accelerates solid cancer trials with ‘new MOA’ CAR-T
• by Son, Hyung-Min Apr 2, 2024 05:54am

• Policy
• 3 more successful Zolgensma treatment cases reported…
• by Lee, Tak-Sun Apr 2, 2024 05:54am

• Policy
• Oppo parties also promise 'drug price system reform'
• by Lee, Jeong-Hwan Apr 2, 2024 05:54am

• Company
• PharmaEssentia reattempts reimb of BESREMi in Korea
• by Eo, Yun-Ho Apr 2, 2024 05:53am

• Policy
• Price reduction dilemma for 'Forxiga' set for withdrawal
• by Lee, Tak-Sun Apr 2, 2024 05:53am

• Policy
• K-drugs’ approval in the Philippines to be expedited
• by Lee, Tak-Sun Apr 1, 2024 05:29am

• Company
• Oral option introduced for psoriasis in Korea
• by Eo, Yun-Ho Apr 1, 2024 05:29am

• Opinion
• [Reporter’s View] Results needed for ‘Ilaris’ on hold
• by Eo, Yun-Ho Apr 1, 2024 05:29am

• Policy
• Prior approval not required for reimb of Strensiq in KOR
• by Lee, Tak-Sun Apr 1, 2024 05:29am

• Policy
• The NHI Trade Union says, 'NHIS should join the DREC'...
• by Lee, Tak-Sun Mar 29, 2024 05:53am